Effect of Cytomegalovirus Prophylaxis with Acyclovir on Renal Transplant Survival

REFERENCES

• Hariharan S, Johnson CP, Bresnehan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342: 605–612
   PubMed Web of Science ®Google Scholar
• Smith SR, Butterly DW, Alexander BD, Greenberg A. Viral infections after renal transplantation. Am J Kidney Dis. 2001; 37: 659–676
   Google Scholar
• Tanabe K, Tokumoto T, Ishikawa N, et al. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation. 1997; 64: 1721–1725
   Google Scholar
• Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001; 12: 848–855
   PubMed Web of Science ®Google Scholar
• Balfour HH, Jr, Chace BA, Stapleton JT, Simmons RL, Fryd D S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989; 320: 1381–1387
   PubMed Web of Science ®Google Scholar
• Barkholt L, Lewensohn-Fuchs I, Ericzon BG, Tyden G, Andersson J. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis. 1999; 1: 89–97
   PubMedGoogle Scholar
• Helantara I, Koskinonen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int. 2006; 19: 893–900
   Google Scholar
• McLaughlin K, Sandhu S, Wu C, Muirhead N, Hollomby D, Jevnikar A. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. Nephrol Dial Transplant. 2005; 20: 176–180
   Google Scholar
• Conlon PJ, Jr, Carmody M, Donohoe J, Spencer S, Smyth E, Walshe JJ. Cytomegalovirus infection as a complication of OKT3 therapy in kidney transplant recipients. Ir J Med Sc 1992; 161: 630–632
   Google Scholar
• Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000; 2: 112–117
   PubMedGoogle Scholar
• Snydman DR, Rubin RH, Werner BG. New developments in cytomegalovirus prevention and management. Am J Kidney Dis. 1993; 21: 217–228
   Google Scholar
• Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis. 2002; 39: 1088–1095
   PubMed Web of Science ®Google Scholar
• Bock GH, Sullivan EK, Miller D, et al. Cytomegalovirus infections following renal transplantation-effects on antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1997; 11: 665–671
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B, Rubenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant. 2004; 4: 928–936
   PubMed Web of Science ®Google Scholar
• Ricart MJ, Malaise J, Moreno A, Crespo M, Fernandez-Cruz L. Cytomegalovirus: Occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 2005; 20(Suppl. 2)25–32
   Google Scholar
• Schneeberger H, Aydemir S, Muller R, et al. Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival. Transpl Int. 2000; 13(Suppl. 1)S354–S358
   Google Scholar
• Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356: 645–649
   PubMed Web of Science ®Google Scholar
• Ketteler M, Preuschof L, Mertz A, et al. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient. Clin Nephrol. 2000; 54: 418–424
   Google Scholar
• Bonnar J, Browne P, Cahill M, et al. A guideline for transfusion of red blood cells in surgical patients. National Blood Users Group, Department of Health, DublinIreland 2000; 1–20
   Google Scholar
• Lo A, Stratta RJ, Egidi MF, et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis. 2001; 3: 8–15
   Google Scholar
• Toupance O, Bouedjoro-Camus MC, Carquin J, et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses. Transpl Int. 2000; 13: 413–419
   PubMed Web of Science ®Google Scholar
• Reisching T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation. 2005; 15: 317–324
   Google Scholar
• Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation. 2001; 71: 764–767
   Google Scholar
• Boratynska M, Banasik M, Watorek E, Patrzalek D, Szyber P, Klinger M. Influence of cytomegalovirus disease on early and late renal graft function. Transplant Proc. 2006; 38: 147–150
   Google Scholar
• Isenberg AL, Shen GK, Singh TP, Hahn A, Conti DJ. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense antiHrejection immunotherapy. Clin Transplant. 2000; 14: 193–198
   Google Scholar